Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cell Therapeutics Gets Biogen Drug

August 27, 2007 | A version of this story appeared in Volume 85, Issue 35

Cell Therapeutics Inc., a Seattle-based biopharmaceutical company, has agreed to acquire U.S. rights to Zevalin, a radioimmunotherapy approved for non-Hodgkin's lymphoma, from Biogen Idec. CTI will pay Biogen Idec $10 million up front and up to $20 million more in milestone payments. Bayer Schering will sell the drug outside the U.S. under an agreement with Biogen Idec. "Zevalin is an effective yet underutilized drug with a favorable tolerability profile," says Jack W. Singer, chief medical officer of CTI. CEO James A. Bianco adds that Zevalin, with U.S. sales of $16.4 million in 2006, will complement pixantrone, a CTI drug currently in Phase III clinical trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.